Building better chimeric antigen receptors for adoptive T cell therapy - PubMed (original) (raw)
Review
Building better chimeric antigen receptors for adoptive T cell therapy
John S Bridgeman et al. Curr Gene Ther. 2010 Apr.
Abstract
The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the T-cell receptor complex (typically CD3zeta) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.
Similar articles
- T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM. Jamnani FR, et al. Biochim Biophys Acta. 2014 Jan;1840(1):378-86. doi: 10.1016/j.bbagen.2013.09.029. Epub 2013 Sep 27. Biochim Biophys Acta. 2014. PMID: 24076235 - Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P. Han X, et al. Mol Ther. 2017 Nov 1;25(11):2466-2476. doi: 10.1016/j.ymthe.2017.07.009. Epub 2017 Jul 20. Mol Ther. 2017. PMID: 28784559 Free PMC article. - Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
Shi H, Sun M, Liu L, Wang Z. Shi H, et al. Mol Cancer. 2014 Sep 21;13:219. doi: 10.1186/1476-4598-13-219. Mol Cancer. 2014. PMID: 25241075 Free PMC article. Review. - Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
Hombach A, Pohl C, Reinhold U, Abken H. Hombach A, et al. Hybridoma. 1999 Feb;18(1):57-61. doi: 10.1089/hyb.1999.18.57. Hybridoma. 1999. PMID: 10211789 Review.
Cited by
- Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy.
Rehman M, Qaiser A, Khan HS, Manzoor S, Ashraf J. Rehman M, et al. Clin Exp Med. 2024 Aug 6;24(1):180. doi: 10.1007/s10238-024-01442-9. Clin Exp Med. 2024. PMID: 39105978 Free PMC article. Review. - Role of T cells in cancer immunotherapy: Opportunities and challenges.
Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, Ahmed SZ, Ema TI, Rahman N, Khan MA, Mizan MFR, Emran TB. Ahmed H, et al. Cancer Pathog Ther. 2022 Dec 20;1(2):116-126. doi: 10.1016/j.cpt.2022.12.002. eCollection 2023 Apr. Cancer Pathog Ther. 2022. PMID: 38328405 Free PMC article. Review. - Unlocking the potential of Tregs: innovations in CAR technology.
Requejo Cier CJ, Valentini N, Lamarche C. Requejo Cier CJ, et al. Front Mol Biosci. 2023 Oct 12;10:1267762. doi: 10.3389/fmolb.2023.1267762. eCollection 2023. Front Mol Biosci. 2023. PMID: 37900916 Free PMC article. Review. - Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
Geng P, Chi Y, Yuan Y, Yang M, Zhao X, Liu Z, Liu G, Liu Y, Zhu L, Wang S. Geng P, et al. Front Cell Dev Biol. 2023 Jun 29;11:1158539. doi: 10.3389/fcell.2023.1158539. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37457288 Free PMC article. Review. - Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
Zhao M, Huang H, He F, Fu X. Zhao M, et al. Front Immunol. 2023 May 18;14:1188277. doi: 10.3389/fimmu.2023.1188277. eCollection 2023. Front Immunol. 2023. PMID: 37275909 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources